Enhancing Outcomes from Major Depression: Using Antidepressant Combination Therapies with Multifunctional Pharmacologic Mechanisms from the Initiation of Treatment
The DOI matches its Crossref record; 56 of the 56 references it cites were found in a registry or an index.
Abstract
Traditional guidelines call for treatment of major depression with a sequence of single antidepressants. Augmentation with a second agent generally only occurs when the first agent is well tolerated and when it also provides at least some symptomatic improvement on its own. Since this standard approach leads to low rates of attaining and sustaining remission by the first agent, with diminishing returns for each subsequent agent, there is growing dissatisfaction with this approach to the treatment of major depression. One new trend is to attempt to enhance the rates of sustained remission from a major depressive episode by combining two therapeutic agents from the very initiation of treatment of a major depressive episode. Traditional treatment of major depression begins with a single “first line” antidepressant, and if it does not work or is not tolerated, trying another and then another. Unfortunately, this strategy results in disappointing remission rates for the first antidepressant (Figure 1), and disappointing rates of maintaining any improvement that is attained by this first agent because of high relapse rates over the next year despite continuing treatment with the first antidepressant (Figure 2A). And that is the good news. The bad news is that with each subsequent antidepressant treatment administered remission rates are progressively reduced (Figure 1). For those patients who do improve, they are progressively less likely to sustain their therapeutic gains despite continuing to take the drug that led to their initial improvement (Figure 2).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Manualized psychotherapy approaches (eg, cognitive behavioral therapy [CBT] and mindfulness therapies) are effective in the acute treatment of cognitive symptoms in MDD.52,53”
From Cognitive Impairment in Major Depressive Disorder (2019) · cites this paper as [53]
Citations
Cites
Goodman and Gilman's the Pharmacological Basis of Therapeutics
Stigelman, W. H., & Pharm, D. (1986) · Military Medicine · doi:10.1093/milmed/151.1.386 · Cited by 6,782
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden, D., Niederehe, G., Thase, M. E., Lavori, P. W., Lebowitz, B. D., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.11.1905 · Cited by 5,643
Cipriani, A., Furukawa, T. A., Salanti, G., Geddes, J. R., Higgins, J. P., Churchill, R., Watanabe, N., Nakagawa, A., Omori, I. M., McGuire, H., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60046-5 · Cited by 1,654
Goodman and Gilman's The Pharmacological Basis of Therapeutics
Fraunfelder, F. T. (1981) · American Journal of Ophthalmology · doi:10.1016/0002-9394(81)90318-4 · Cited by 1,331
Further evaluation of the Dutch supervision system for suicides of mental health care users
(2013) · EUR Research Repository (Erasmus University Rotterdam) · doi:10.1176/appi · Cited by 1,030
The STAR*D project results: A comprehensive review of findings
Warden, D., Rush, A. J., Trivedi, M. H., Fava, M., & Wisniewski, S. R. (2007) · Current Psychiatry Reports · doi:10.1007/s11920-007-0061-3 · Cited by 727
Velligan, D. I., Weiden, P. J., Sajatovic, M., Scott, J. L., Carpenter, D., Ross, R., & Docherty, J. P. (2009) · PubMed · Cited by 625
Fava, M., McCall, W. V., Krystal, A., Wessel, T., Rubens, R., Caron, J., Amato, D., & Roth, T. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.01.016 · Cited by 480
Residual symptoms in depressed patients who respond acutely to fluoxetine
Nierenberg, A. A., Keefe, B. R., Leslie, V. C., Alpert, J. E., Pava, J. A., Worthington, J. J., Rosenbaum, J. F., & Fava, M. (1999) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v60n0403 · Cited by 470
Hypomethylation of MB-COMT promoter is a major risk factor for schizophrenia and bipolar disorder
Abdolmaleky, H. M., Cheng, K.-H., Faraone, S. V., Wilcox, M., Glatt, S. J., Gao, F., Smith, C. L., Shafa, R., Aeali, B., Carnevale, J., et al. (2006) · Human Molecular Genetics · doi:10.1093/hmg/ddl253 · Cited by 462
Research works printed but not linked: 5
- Bares, 2009, Neuro Endocrinol Lett
- 10.1002/(SICI)1096-8628(19970919)74:5<526::AID-AJMG14>3.0.CO;2-E · DOI · Paper page
- Stahl, 2009, Stahls Essential Psychopharmacology Preserver's Guide
- 10.1177/026988110401800415 · doi:10.1177/026988110401800415
- Stahl, 2008, Stahls Essential Psychopharmacocology
Cited by
Cognitive Impairment in Major Depressive Disorder
Pan, Z., Park, C., Brietzke, E., Zuckerman, H., Rong, C., Mansur, R. B., Fus, D., Subramaniapillai, M., Lee, Y., & McIntyre, R. S. (2019) · CNS Spectrums · doi:10.1017/s1092852918001207 · Cited by 320
“The well-established monoamine abnormalities in MDD likely contribute to impaired cellular signaling and neurocircuit deficits.(19) Peripheral inflammation and systemic activation of proinflammatory cytokines may also play a role in the pathogenesis of cognitive symptoms.”
BackgroundCognitive dysfunction in major depressive disorder: a state-of-the-art clinical review
Bortolato, B., Carvalho, A., & McIntyre, R. (2015) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527313666141130203823 · Cited by 181
“SSRI or SNRI) may exert a beneficial effect on cognitive impairment in individuals with MDD [116], converging evidence indicates that cognitive deficits are often sub-optimally treated with conventional psychopharmacological treatments and persist even in remitted phases of the disorder [117].”
BackgroundPehrson, A. L., & Sanchez, C. (2014) · CNS Spectrums · doi:10.1017/s1092852913000540 · Cited by 161
“In recent years, antidepressant combination therapies with multifunctional pharmacologic mechanisms have been used to enhance therapeutic outcomes.(1) Some combinations include an SSRI plus the 5-HT1A receptor and b adrenergic receptor antagonist pindolol,(2) or SSRIs augmented with atypical antipsychotics.”
Bortolato, B., F. Carvalho, A., K. Soczynska, J., I. Perini, G., & S. McIntyre, R. (2015) · Current Neuropharmacology · doi:10.2174/1570159x13666150630171433 · Cited by 142
“The well-established abnormalities in monoamine systems in MDD are likely to mirror aberrant cellular signaling within these circuits and are involved in the development of attentional deficits and executive dysfunction [19].”
BackgroundCarvalho, A. F., Berk, M., Hyphantis, T. N., & McIntyre, R. S. (2014) · Psychotherapy and Psychosomatics · doi:10.1159/000357500 · Cited by 123
Metadata
- Authors
- Stahl, S. M.
- Affiliations
- University of California San Diego (US)
- Corresponding author
- Stahl, Stephen M.
- ORCID
- Stahl, Stephen M.
- Venue
- CNS Spectrums
- Publisher
- Cambridge University Press (CUP)
- Published
- 2010-02
- Volume
- 15
- Issue
- 2
- Pages
- 79-94
- ISSN
- 1092-8529 (ISSN-L)
- 2165-6509
- OpenAlex
- W2461699656
- Cited by
- 40
- References
- 56
- Citations by year
- 2024: 3 · 2022: 1 · 2021: 1 · 2019: 1 · 2018: 5 · 2016: 1 · 2015: 5 · 2014: 7 · 2013: 6 · 2012: 6
- FWCI
- 3.77
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- CNS Spectrums (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Health Sciences › Medicine › Psychiatry and Mental health › Mental Health Treatment and Access
- Keywords
- major depressive disorder, antidepressant combination therapy, augmentation therapy, first-line antidepressants, remission rate, relapse, sustained remission, treatment-resistant depression
- MeSH terms
- Antidepressive Agents, Depressive Disorder, Major, Major Depressive Disorder, Drug Therapy, Combination, Humans, Models, Biological, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Enhancing Outcomes from Major Depression: Using Antidepressant Combination Therapies with Multifunctional Pharmacologic Mechanisms from the Initiation of Treatment. https://app.cochat.ai/papers/10.1017/s1092852900027334
- The paper
- Stahl, S. M. (2010). Enhancing Outcomes from Major Depression: Using Antidepressant Combination Therapies with Multifunctional Pharmacologic Mechanisms from the Initiation of Treatment. CNS Spectrums. https://doi.org/10.1017/s1092852900027334
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.